드러그인포 약품요약정보

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

655603430[A03555751] [보험코드에 따른 약품기본정보 직접조회]
\0 원/800+200mL/백(2016.12.01)(현재약가)
\7,806 원/800+200mL/백(2016.01.01)(변경전약가)
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

격막에 의해 두 부분으로 분리된 하나의 투명한 플라스틱백에 충진된 양쪽 모두 무색투명한 액제 [제형정보 확인]

포장·유통단위

자사포장단위에 따름

포장·코드단위

약품규격	단위	포장형태	대표코드	표준코드	비고
1000밀리리터	1 기타	백	8806556034306	8806556034313

주성분코드

497500BIJ [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]

허가사항 원문조회

[허가사항 원문조회]

효능효과

[적응증 별 검색]

경구 또는 위장관 영양보급이 불가능 또는 불충분하거나 또는 제한되어 경정맥 영양공급을 실시해야 하는 환자들에게 수분, 전해질, 아미노산 및 칼로리 보급

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
경중심정맥 영양 보급에 개시시에 내당능이 불분명한 경우와 저하한 경우의 개시액으로 침습시 등에서 내당능이 저하되고 포도당을 제한할 필요가 있는 경우의 유지액으로 사용한다.
사용 시 격벽부를 개통하고 A액 및 B액을 혼합하여 유지액 또는 개시액으로 한다.
일반적으로 성인 1일 2000 mL 개시액 또는 유지액을 24시간 동안 중심정맥 내에 지속 점적 주입한다.
연령, 증상 및 체중에 따라 적절히 증감한다.

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

주요약물 상호작용

[조회]

금기

1) 고나트륨혈증 환자(전해질조성에 따른 고나트륨혈증을 악화시킬 우려가 있다.)
2) 고염소혈증 환자(전해질조성에 따라 고염소혈증을 악화시킬 우려가 있다.)
3) 고칼륨혈증, 핍뇨, 에디슨병, 고질소혈증 환자(신장에서 칼륨배설장애에 의한 증상을 악화시킬 우려가 있다.)
4) 고인산혈증, 부갑상선기능저하증 환자(전해질조성에 따른 고인산혈증을 악화시킬 우려가 있다.)
5) 고마그네슘혈증, 갑상선기능저하증 환자(전해질조성에 따른 고마그네슘혈증을 악화시킬 우려가 있다.)
6) 고칼슘혈증 환자(전해질조성에 따른 고칼슘혈증을 악화시킬 우려가 있다.)
7) 강심배당체 투여를 받고 있는 환자
8) 간성혼수 또는 간성혼수의 우려가 있는 환자(아미노산 불균형을 조장하고, 간성혼수를 악화 또는 유발시킬 우려가 있다.)
9) 중등의 신장애가 있는 환자(질소 및 물부하의 증가에 따른 신기능을 악화시킬 우려가 있다.)
10) 아미노산 대사이상 환자(아미노산 불균형을 조장할 우려가 있다.)
11) 심근경색및 그 병력이 있는 환자

신중투여

1) 균혈증 환자(카테터가 2차감염소가 되는 경우가 있으므로, 패혈증 또는 패혈증성 쇽을 일으킬 우려가 있다.)
2) 고장성탈수증 환자(전해질조성에 따라 탈수증을 조장할 우려가 있다.)
3) 신질환에 기초한 신부전이 있는 환자(수분, 전해질의 조절장애에 따른 순환부전을 일으킬 우려가 있다.)
4) 중증 화상의 환자(순환혈액량의 증가에 따른 심부하 증가의 우려가 있다.)
5) 고칼륨혈증을 수반하지 않는 신부전이 있는 환자(나트륨부하에 따른 칼륨배설장애, 질소부하에 따른 BUN의 상승에 의해 신부전증상을 악화시킬 우려가 있다.)
6) 심부전이 있는 환자(순환혈액량의 증가에 따른 심부하 증가의 우려가 있다.)
7) 폐색성요로질환에 따라 요량이 감소되고 있는 환자(수분배설장애에 따라 원래 병의 증상을 악화시킬 우려가 있다.)
8) 당뇨병 환자(고혈당을 일으킬 우려가 있다.)
9) 요붕증 환자(수분, 전해질의 과량투여에 따라 수분, 전해질 이상을 일으킬 우려가 있다.)
10) 고도의 산증 환자(전해질조성에 따른 산증을 악화시킬 우려가 있다.)
11) 췌장염, 췌경화증, 췌종양 등의 췌장장애가 있는 환자(고혈당 등 내당능 이상을 일으킬 우려가 있다.)
12) 이 약은 아황산수소나트륨이 함유되어 있어 아나필락시와 같은 알레르기를 일으킬 수 있으며 일부 감수성 환자에서는 생명을 위협할 정도 또는 이보다 약한 천식발작을 일으킬 수 있다. 일반 사람에서의 아황산감수성에 대한 총괄적인 빈도는 알려지지 않았으나 낮은 것으로 보이며 아황산감수성은 비천식환자보다 천식환자에서 빈번한 것으로 나타났다.

이상반응

1) 산증 : 다른 고칼로리 수액제제 투여 중에 중증의 산증이 나타날 수 있으므로, 투여 중에는 관찰을 충분히 하여 증상이 나타나는 경우에는 적절한 처치를 한다.
2) 대량급속투여 : 뇌부종, 폐부종, 말초부종, 물중독이 나타날 수 있다.
3) 고혈당 : 이 약은 고농도의 포도당 함유 제제이므로, 때때로 중증의 고혈당, 고삼투압이뇨, 구갈이 나타날 수 있다. 이러한 증상이 나타나는 경우에는 인슐린 투여 등 적절한 처치를 한다.
4) 간기능 이상 : 이 약은 고농도의 포도당 함유 제제이므로, 때때로 당의 과부하에 의한다고 생각되는 AST, ALT 등의 경도이상이 보일 수 있다.
5) 고칼륨혈증 : 때때로 고칼륨혈증이 나타날 수 있다.
6) 과민반응 : 발진 등(빈도불명)이 나타나는 경우에는 투여를 중단한다.
7) 시판후조사결과 경증 또는 중등증보다 만성의 급성악화 환자에서, 신장애가 없는 환자보다 있는 환자에서 각각 이상반응 발현증례율이 통계적으로 유의하게 높게 나타났다.

[간기능이상 약물 및 주의사항] [신기능이상 약물 및 주의사항]

[주요 이상반응정보]

상호작용

강심배당체(디기톡신, 디곡신, 라나토시트C)와 병용할 때 수액성분중의 칼슘이 디기탈리스제제의 심장에의 작용을 증강시켜 부정맥 등의 디기탈리스 중독(전신권태감, 식욕부진, 구역, 두통, 구토, 설사, 황시, 부정맥)을 일으킬 우려가 있으므로 이와 같은 증상이 보이는 경우에는 투여를 중지한다.

Off-label Usage

[조회]

Related FDA Approved Drug

기준 성분:GLYCINE
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER (GLYCINE)
GLYCINE 1.5% IN PLASTIC CONTAINER (GLYCINE)
기준 성분:DIBASIC POTASSIUM PHOSPHATE
기준 성분:DEXTROSE
ALCOHOL 10% AND DEXTROSE 5% (ALCOHOL; DEXTROSE)
ALCOHOL 5% AND DEXTROSE 5% (ALCOHOL; DEXTROSE)
ALCOHOL 5% IN D5-W (ALCOHOL; DEXTROSE)
ALCOHOL 5% IN DEXTROSE 5% IN WATER (ALCOHOL; DEXTROSE)
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE)
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE)
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE)
BSS PLUS (CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE)
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER (AMINO ACIDS; DEXTROSE)
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER (AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE)
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 10% IN PLASTIC CONTAINER (DEXTROSE)
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 2.5% IN PLASTIC CONTAINER (DEXTROSE)
DEXTROSE 20% IN PLASTIC CONTAINER (DEXTROSE)
DEXTROSE 25% (DEXTROSE)
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 30% IN PLASTIC CONTAINER (DEXTROSE)
DEXTROSE 38.5% IN PLASTIC CONTAINER (DEXTROSE)
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 40% IN PLASTIC CONTAINER (DEXTROSE)
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER (DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE)
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE)
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE)
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE)
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE)
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE)
DEXTROSE 5% IN PLASTIC CONTAINER (DEXTROSE)
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER (CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (DEXTROSE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K) (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075% (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER (DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE)
DEXTROSE 50% IN PLASTIC CONTAINER (DEXTROSE)

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
성분코드	M040378/아황산수소나트륨 / M040426/염화나트륨 2.920그램 / M040554/초산칼륨 2.160그램 / M040702/포도당 120.0그램 / M040802/황산아연 5.752밀리그램 / M080356/황산마그네슘수화물 0.740그램 / M088656/글리신 2.140그램 / M103058/L-글루타민산 1.300그램 / M103060/L-트레오닌 1.300그램 / M103077/L-아르기닌 1.580그램 / M103078/L-아스파라긴산 0.760그램 / M204435/L-세린 0.440그램 / M204437/L-시스테인 0.200그램 / M204442/L-페닐알라닌 1.870그램 / M209360/L-발린 0.900그램 / M209366/L-알라닌 1.240그램 / M214274/L-트리프토판 0.260그램 / M214313/L-티로신 0.070그램 / M214747/초산-L-리신 2.480그램 / M214861/L-프롤린 0.660그램 / M215288/L-히스티딘 1.200그램 / M218567/L-메티오닌 0.700그램 / M222530/L-이소류신 1.120그램 / M222531/L-류신 2.500그램 / M222935/글루콘산칼슘수화물 1.792그램 / M242353/인산이수소칼륨 1.088그램 /
주성분코드	497500BIJ [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]
대표코드	8806556034306
BIT 약효분류	비경구영양제(Parenteral Nutritional Products)
ATC 코드	amino acids / B05BA01 [코드분류상세설명] [ATC코드예측]
복지부분류코드	325 (단백아미노산제제 )
주성분코드 분석 및 중복처방 검토	[주성분코드 분석 및 중복처방 검토]
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	655603430[A03555751] [보험코드에 따른 약품기본정보 직접조회] \0 원/800+200mL/백(2016.12.01)(최신약가) \7,806 원/800+200mL/백(2016.01.01)(변경전약가) [상병코드조회] [질병코드집 다운로드]
제품성상	격막에 의해 두 부분으로 분리된 하나의 투명한 플라스틱백에 충진된 양쪽 모두 무색투명한 액제 [제형정보 확인]
포장·유통단위	자사포장단위에 따름
보관방법	밀봉용기, 실온(1～30℃)보관
동일주성분코드 검색순위	유료정보입니다.

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

신장애, 간장애시
용량조절

유료정보입니다.

Pharmacokinetics

유료정보입니다.

보관상 주의

조제시 주의

심사정보

항목

내용

심사사례

위 악성신생물및 간내담관암종 상병으로 투여된 단백아미노산제제의 투여용량 및 간격에 대하여
■ 청구내역

구분	A사례(M/56세)	B사례(F/73세)
상병명	위의 악성신생물 소장의 속발성 악성신생물	간내담관암종 간의속발성암, 협심증
주요청구내역	[주사료] 리포피드주사 10% 1× 5 인트라리포즈주 20% 1× 2 크레타민주 1× 1 뉴트리플렉스페리40주 1× 1, 2× 4, 3× 12 [처치및수술료] 자667 경피경간담즙배액술 × 1 자4 산소흡입 1× 2	[주사료] 알부민주 20% 100ml 1× 2 토파뉴솔 10% 1× 1 인트라리포즈 10% 1× 2 피엔트윈주3호 1× 60 → 1× 27인정 자4 산소흡입 1× 42

■ 진료내역

A사례(남자/56세)

     C.C : Jaundice
     P.I : Known AGC(Advancedgastric ca) 환자로 FP #3 이후 jaundice, fever 주소로 내원함.
          CT상 disease progression
     Imp : AGC, Obstructivejaundice due to biliary metastasis s/p PTBD
     입원후 경과
        AGC 환자로 본원에서 7월 24일 open &close 및 palliative gastrojejunostomy시행후 chemotherapy(5FU + CDDP, 3차 시행)후 disease progression으로 obstructive jaundice 생김.
        이에 대하여 PTBD 시행하였고 현재 oral intake poor 하여 IV nutritional support시행중임.
     - 약제투여기록지 (체중 : 66.2kg)

구분	11/12	13	14	15	16	17	18	19	20	21	22	23
뉴트리플렉스페리40							1	2	2	2	2	2
인트라리포즈
리포피드
크레타민				1
알부민								1	1			1
protein/albumin	5.6/2.8	2.1	2.3	2.6	4.9/2.5	2.6		5.0/2.5	2.5	2.7		5.8/2.9
oral intake		80	160	240	-	120	130	90	100	-	-	140
I/O (PTBD)		4152/3170	4304/4890	4740/4120	4500/ 1640	4050/3350	3180/2700	3090/ 2230	3700/3410	3500/3130	3500/3940	3740/ 3900

구분	24	25	26	27	28	29	30	12/1	2	3	4	5
뉴트리플렉스페리40	3	3	3	3	3	3	3	3	3	3	3	3
인트라리포즈		1	1
리포피드			1			1	1		1	1
크레타민
알부민
protein/albumin							7.3/-
oral intake	50	50	-	50	80	190	150	20	140	100	-
I/O (PTBD)	3900/3450	3800/3170	4250/3450	3250/2980	3280/2800	3890/3630	3850/4390	3200/2980	3140/3560	3800/3560	3200/3090

B 사례(여자/73세)

     C.C: abdominal distensionfor 4days, poor oral intake
     PHx : High BP for 15yrs
          전년 10.5 - 10.25 Cholangio carcinoma, High BP로 입원. 현재 가정간호사 care중임.
     P.I : 내원 4일전 abdominal distension과 poor oral intake가있고 dyspnea 증상이 있어 ER visit
     IMP : Cholangiocarcinomawith liver meta. HBP
     Progress :
        12.14Ascites tapping(yellowish : 4bottle)
        12.28Terminal care하고있는 환자 상태 설명
        1.5 보호자들이 Lab은더 이상 하고 싶지 않다고 설명
        1.20Blood에서 S. aureus발견
        2.1Anti를 po로 바꾼 후 다시 fever발생
        2.6tachypnea 심해짐
        2.10Chest AP 상 Rt atelectasis 소견 있음.
        2.13Wanted discharge

구분	12/14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
PNT10	1	1	1		1	1	1	1	1	1	1	1	2	1	1	2	1
인트라리포즈
토파뉴솔
알부민					1				1
protein/albumin	6.8/2.8	6.5/2.8							6.3/2.7						6.3/3.0
oral intake	150	460	770	680	1020	880	850	1200	930	970	650	750	850	900	730	930	980
I/O	950/900	1950/ 1110	2970/1400	2080/2100	2680/3400	2947/2400	2794/2500	2825/2500	3150/ 2800	3017/3000	2836/2800	2800/2600	2880/2300	2890/2600	2880/2800	3090/2700	2460/2400

구분	31	1/1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
PNT10	1	1	1		1	1	1	1	1	1	1	1	1	1	1	1	1
인트라리포즈
토파뉴솔
알부민
protein/albumin
oral intake	500	540	540	700	800	900	1200	600	800	1150	750	700	700	750	900	600	1250
I/O	2650/1750	2140/2200	2140/2300	2600/2600	2000/1500	2400/2200	3000/2400	2300/2100	2900/2000	2660/2500	2250/2000	2350/2400	2450/2200	2350/2200	2600/2000	2300/1900	2750/2000

구분	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31
PNT10	1	1	1		1	1	1	1	1	1		2	1		1
인트라리포즈
토파뉴솔
알부민
protein/albumin								6.0/2.8
oral intake	850	1300	900	950	270	450	800	550	1350	900	800	600	710	650	600
I/O	1750/2400	2900/2700	1450/2000	2650/2350	1570/1500	1850/1800	2300/2000	1650/1600	2410/2600	2400/2400	1900/2400	2550/2000	2310/1600	3360/2100	1650/1500

구분	2/1	2	3	4	5	6	7	8	9	10	11	12	13	14
PNT10	2	1	1			1	1	1	1	1	1	1	1
인트라리포즈			1								1
토파뉴솔						1
알부민
protein/albumin
oral intake	850	150	100	300	200	550	0	0	230	150	100	250	150
I/O	1840/ 950	1750/ 900	2500/ 1250	2200/ 630	850/ 900	3050/ 1300	2400/ 989	2290/ 598	2540/ 2040	2300/ 1335	2875/ 950	3200/ 1700

의사소견서 : Cachexia심하고poor oral intake, malnutrition 있어 피엔트윈주(PNT10) 주입함.
■ 참고
   ○ 고시 제2001-28호(2001.6.8) 단백아미노산제제의 요양급여기준
   ○ AmericanGastroenterological Association medical position statement: parenteralnutrition.
     Gastroenterology 2001 Oct;121(4):966-9.
■ 심의내용
   위 악성신생물(Advanced gastricca, biliary metastasis, A사례) 및 간내담관암종(Cholangiocarcinoma liver meta, B사례) 상병에경구섭취 부족하여 영양공급을 위해 단백아미노산제제(A사례:뉴트리플렉스페리40주, B사례:피엔트윈주3호)를 투여한 동 건은 경구 영양투여량 등을 고려하여 A사례는 매일 투여한 대로 인정하되 투여량은 1일 2병 인정하고, B사례는 주 3병으로인정함.
[2003.1.20 진료심사평가위원회]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
독성정보	Calcium에 대한 독성정보 : 정보보기 L-Glutamic Acid에 대한 독성정보 : 정보보기 Potassium에 대한 독성정보 : 정보보기 출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action	Calcium에 대한 Mechanism_Of_Action 정보 Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. More than 500 human proteins are known to bind or transport calcium. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Parathyroid hormone (secreted from the parathyroid gland) regulates the resorption of Ca2+ from bone. Calcitonin stimulates incorporation of calcium in bone, although this process is largely independent of calcitonin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. The currently recommended calcium intake is 1,500 milligrams per day for women not taking estrogen and 800 milligrams per day for women on estrogen. There is close to 300 milligrams of calcium in one cup of fluid milk. Calcium carbonate is currently the best and least expensive form of calcium supplement available. potassium에 대한 Mechanism_Of_Action 정보 Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential?봞 "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity. Glycine에 대한 Mechanism_Of_Action 정보 In the CNS, there exist strychnine-sensitive glycine binding sites as well as strychnine-insensitive glycine binding sites. The strychnine-insensitive glycine-binding site is located on the NMDA receptor complex. The strychnine-sensitive glycine receptor complex is comprised of a chloride channel and is a member of the ligand-gated ion channel superfamily. The putative antispastic activity of supplemental glycine could be mediated by glycine's binding to strychnine-sensitive binding sites in the spinal cord. This would result in increased chloride conductance and consequent enhancement of inhibitory neurotransmission. The ability of glycine to potentiate NMDA receptor-mediated neurotransmission raised the possibility of its use in the management of neuroleptic-resistant negative symptoms in schizophrenia. Animal studies indicate that supplemental glycine protects against endotoxin-induced lethality, hypoxia-reperfusion injury after liver transplantation, and D-galactosamine-mediated liver injury. Neutrophils are thought to participate in these pathologic processes via invasion of tissue and releasing such reactive oxygen species as superoxide. In vitro studies have shown that neutrophils contain a glycine-gated chloride channel that can attenuate increases in intracellular calcium and diminsh neutrophil oxidant production. This research is ealy-stage, but suggests that supplementary glycine may turn out to be useful in processes where neutrophil infiltration contributes to toxicity, such as ARDS. L-alanine에 대한 Mechanism_Of_Action 정보 L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance. L-arginine에 대한 Mechanism_Of_Action 정보 Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production. L-cysteine에 대한 Mechanism_Of_Action 정보 Although classified as a non-essential amino acid cysteine may be essential for infants, the elderly, and individuals with certain metabolic disease or who suffer from malabsorption syndromes. Cysteine can usually be synthesized by the human body under normal physiological conditions if a sufficient quantity of methionine is available. Due to the ability of thiols to undergo redox reactions, cysteine has antioxidant properties. Cysteine's antioxidant properties are typically expressed in the tripeptide glutathione, which occurs in humans as well as other organisms. The systemic availability of oral glutathione (GSH) is negligible; so it must be biosynthesized from its constituent amino acids, cysteine, glycine, and glutamic acid. Glutamic acid and glycine are readily available in the diets of most industrialized countries, but the availability of cysteine can be the limiting substrate. Cysteine is also an important source of sulfide in human metabolism. The sulfide in iron-sulfur clusters and in nitrogenase is extracted from cysteine, which is converted to alanine in the process. In a 1994 report released by five top cigarette companies, cysteine is one of the 599 additives to cigarettes. Its use or purpose, however, is unknown, like most cigarette additives. Its inclusion in cigarettes could offer two benefits: Acting as an expectorant, since smoking increases mucus production in the lungs; and increasing the beneficial antioxidant glutathione (which is diminished in smokers). L-histidine에 대한 Mechanism_Of_Action 정보 Since the actions of supplemental L-histidine are unclear, any postulated mechanism is entirely speculative. However, some facts are known about L-histidine and some of its metabolites, such as histamine and trans-urocanic acid, which suggest that supplemental L-histidine may one day be shown to have immunomodulatory and/or antioxidant activities. Low free histidine has been found in the serum of some rheumatoid arthritis patients. Serum concentrations of other amino acids have been found to be normal in these patients. L-histidine is an excellent chelating agent for such metals as copper, iron and zinc. Copper and iron participate in a reaction (Fenton reaction) that generates potent reactive oxygen species that could be destructive to tissues, including joints. L-histidine is the obligate precursor of histamine, which is produced via the decarboxylation of the amino acid. In experimental animals, tissue histamine levels increase as the amount of dietary L-histidine increases. It is likely that this would be the case in humans as well. Histamine is known to possess immunomodulatory and antioxidant activity. Suppressor T cells have H2 receptors, and histamine activates them. Promotion of suppressor T cell activity could be beneficial in rheumatoid arthritis. Further, histamine has been shown to down-regulate the production of reactive oxygen species in phagocytic cells, such as monocytes, by binding to the H2 receptors on these cells. Decreased reactive oxygen species production by phagocytes could play antioxidant, anti-inflammatory and immunomodulatory roles in such diseases as rheumatoid arthritis. This latter mechanism is the rationale for the use of histamine itself in several clinical trials studying histamine for the treatment of certain types of cancer and viral diseases. In these trials, down-regulation by histamine of reactive oxygen species formation appears to inhibit the suppression of natural killer (NK) cells and cytotoxic T lymphocytes, allowing these cells to be more effective in attacking cancer cells and virally infected cells. L-isoleucine에 대한 Mechanism_Of_Action 정보 (Applies to Valine, Leucine and Isoleucine) This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. L-leucine에 대한 Mechanism_Of_Action 정보 This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. L-lysine에 대한 Mechanism_Of_Action 정보 Proteins of the herpes simplex virus are rich in L-arginine, and tissue culture studies indicate an enhancing effect on viral replication when the amino acid ratio of L-arginine to L-lysine is high in the tissue culture media. When the ratio of L-lysine to L-arginine is high, viral replication and the cytopathogenicity of herpes simplex virus have been found to be inhibited. L-lysine may facilitate the absorption of calcium from the small intestine.
Pharmacology	potassium에 대한 Pharmacology 정보 Not Available Glycine에 대한 Pharmacology 정보 Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system. L-alanine에 대한 Pharmacology 정보 Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids. L-arginine에 대한 Pharmacology 정보 Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair. L-cysteine에 대한 Pharmacology 정보 Due to this ability to undergo redox reactions, cysteine has antioxidant properties. Cysteine is an important source of sulfur in human metabolism, and although it is classified as a non-essential amino acid, cysteine may be essential for infants, the elderly, and individuals with certain metabolic disease or who suffer from malabsorption syndromes. Cysteine may at some point be recognized as an essential or conditionally essential amino acid. L-histidine에 대한 Pharmacology 정보 Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing. L-isoleucine에 대한 Pharmacology 정보 They provide ingredients for the manufacturing of other essential biochemical components in the body, some of which are utilized for the production of energy, stimulants to the upper brain and helping you to be more alert. L-leucine에 대한 Pharmacology 정보 An essential amino acid. (Claim) Leucine helps with the regulation of blood-sugar levels, the growth and repair of muscle tissue (such as bones, skin and muscles), growth hormone production, wound healing as well as energy regulation. It can assist to prevent the breakdown of muscle proteins that sometimes occur after trauma or severe stress. It may also be beneficial for individuals with phenylketonuria - a condition in which the body cannot metabolize the amino acid phenylalanine L-lysine에 대한 Pharmacology 정보 Insures the adequate absorption of calcium; helps form collagen ( which makes up bone cartilage & connective tissues); aids in the production of antibodies, hormones & enzymes. Recent studies have shown that Lysine may be effective against herpes by improving the balance of nutrients that reduce viral growth. A deficiency may result in tiredness, inability to concentrate, irritability, bloodshot eyes, retarded growth, hair loss, anemia & reproductive problems.
Metabolism	potassium에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Cytochrome P450 11B2 (CYP11B2) L-cysteine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available L-histidine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available L-isoleucine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available L-lysine에 대한 Metabolism 정보 # Phase_1_Metabolizing_Enzyme:Not Available
Absorption	potassium에 대한 Absorption 정보 Not Available Glycine에 대한 Absorption 정보 Absorbed from the small intestine via an active transport mechanism. L-arginine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism. L-histidine에 대한 Absorption 정보 Absorbed from the small intestine via an active transport mechanism requiring the presence of sodium. L-isoleucine에 대한 Absorption 정보 Absorbed from the small intestine by a sodium-dependent active-transport process L-lysine에 대한 Absorption 정보 Absorbed from the lumen of the small intestine into the enterocytes by an active transport process
Pharmacokinetics	Calcium Gluconate의 약물동력학자료 흡수 : 정맥 및 근육주사: 칼슘염은 직접 혈류로 흡수된다. 경구 : 비타민 D가 필요 용해되어 이온화 형으로 흡수 산성환경에서 흡수증가 분포 : 태반통과 유즙분비 소실 : 흡수되지 않은 칼슘은 주로 변으로 배설 신배설 : 20 % Magnesium Sulfate의 약물동력학자료 경구 : 사하작용 발현시간 : 1-2 시간 이내 근육주사 : 작용발현시간 : 1시간 작용지속시간 : 3-4 시간 정맥주사 : 작용발현시간 : 즉시 발현 작용지속시간 : 30분 소실 : 주로 대변으로 배설된다. 흡수된 magnesium은 신속하게 신장으로 배설된다. Sodium Chloride의 약물동력학자료 분포 : 전신으로 분포 소실 : 주로 뇨배설, 땀, 눈물, 타액으로도 분비됨 L-methionine의 약물동력학자료 대사 : S-adenosylmethionine을 거쳐 homocysteine으로 전환된다. 그 후 80%가 cystathione, cysteine, taurine, inorganic sulphate로 점차로 대사된다. L-glutamic acid의 약물동력학자료 분포 : 대부분이 골격근에서 합성되고 저장된다. L-arginine의 약물동력학자료 최고 혈중농도 도달 : 경구 : 2시간 최대 효과 발현 : 당뇨 진단 : 정맥주사 : 20-45 분 혈당의 최고 상승은 20분 후에 나타나며, 인슐린의 최대 상승은 20-30 분 후에 나타나며 glucagon은 30-45 분 후에 나타난다. 성장호르몬 보유 진단 : 정맥주사 : 1-2 시간 Arginine 30 g을 30분간 정맥주사 후 성장호르몬의 최대 상승이 약 1-2 시간 후에 나타난다. 작용 지속 시간 : 정맥주사 : 1시간 흡수 : 위장관에서 잘 흡수됨 대사 : 간에서 arginase에 의해 guanidino group이 가수분해되어 urea와 ornithine을 생성한다. Ornithine은 궁극적으로 glucose 생성에 이용된다. 소실 : 신장 : 사구체로 여과되고 신세뇨관으로 재흡수된다. 반감기 : 1.2-2 시간 Zinc Sulfate의 약물동력학자료 체내 함량 : 2-3 g 흡수 : 상부 장관에서 20-30% 흡수됨 분포 : 근육, 뼈, 모발, 손톱, 전립선, 정자, 맥락막 질환에 분포 주로 세포내 저장됨 (75-88%) 소실 : 주로 대변배설(2-3 mg/day, 췌장액, 위장관액을 통해 소실됨), 소량만이 뇨배설됨 Dextrose의 약물동력학자료 최고혈중농도 도달 시간 : 경구 : 40분 흡수 : 경구 : 위장관에서 신속히 흡수 분포 : 체조직에 모두 분포되어 사용됨 대사 : 이산화탄소와 물로 산화되며 에너지를 방출함 Aminoacetic Acid(Glycine)의 약물동력학자료 대사 : Glycine은 단백, creatinine, glycocholic acid, glutathione, uric acid, heme 등의 합성에 관여한다. 체내에서의 분해는 여러단계로 이루어지며 주된 경로는 가역적인 산화적 분해이다. Serine이 정상적인 분해산물이다. 혈장 반감기 : 85분
Biotransformation	Glycine에 대한 Biotransformation 정보 Hepatic L-arginine에 대한 Biotransformation 정보 Some metabolism of L-arginine takes place in the enterocytes. L-arginine not metabolized in the enterocytes enters the portal circulation from whence it is transported to the liver, where again some portion of the amino acid is metabolized. L-cysteine에 대한 Biotransformation 정보 Not Available L-isoleucine에 대한 Biotransformation 정보 Hepatic L-lysine에 대한 Biotransformation 정보 Hepatic
Toxicity	potassium에 대한 Toxicity 정보 Not Available Glycine에 대한 Toxicity 정보 ORL-RAT LD₅₀ 7930 mg/kg, SCU-RAT LD₅₀ 5200 mg/kg, IVN-RAT LD₅₀ 2600 mg/kg, ORL-MUS LD₅₀ 4920 mg/kg; Doses of 1 gram daily are very well tolerated. Mild gastrointestinal symptoms are infrequently noted. In one study doses of 90 grams daily were also well tole. L-arginine에 대한 Toxicity 정보 Oral supplementation with L-arginine at doses up to 15 grams daily are generally well tolerated. The most common adverse reactions of higher doses from 15 to 30 grams daily are nausea, abdominal cramps and diarrhea. Some may experience these symptoms at lower doses. L-cysteine에 대한 Toxicity 정보 Not Available L-histidine에 대한 Toxicity 정보 ORL-RAT LD₅₀ > 15000 mg/kg, IPR-RAT LD₅₀ > 8000 mg/kg, ORL-MUS LD₅₀ > 15000 mg/kg, IVN-MUS LD₅₀ > 2000 mg/kg; Mild gastrointestinal side effects. L-isoleucine에 대한 Toxicity 정보 Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs L-lysine에 대한 Toxicity 정보 Not Available
Drug Interactions	Calcium에 대한 Drug_Interactions 정보 Alendronate Formation of non-absorbable complexesAmprenavir The antiacid decreases the absorption of amprenavirAtazanavir This gastric pH modifier decreases the levels/effects of atazanavirChloroquine The antiacid decreases the absorption of chloroquineCiprofloxacin Formation of non-absorbable complexesDapsone Formation of non-absorbable complexesDelavirdine The antiacid decreases the effect of delavirdineDemeclocycline Formation of non-absorbable complexesDoxycycline Formation of non-absorbable complexesEnoxacin Formation of non-absorbable complexesFosamprenavir The antiacid decreases the absorption of amprenavirGrepafloxacin Formation of non-absorbable complexesIbandronate Formation of non-absorbable complexesIndinavir The antiacid decreases the absorption of indinavirItraconazole The antacid decreases the effect of the imidazoleKetoconazole The antacid decreases the effect of the imidazoleLevofloxacin Formation of non-absorbable complexesLevothyroxine Calcium decreases absorption of levothyroxineLomefloxacin Formation of non-absorbable complexesMethacycline Formation of non-absorbable complexesMinocycline Formation of non-absorbable complexesMoxifloxacin Formation of non-absorbable complexesNorfloxacin Formation of non-absorbable complexesOfloxacin Formation of non-absorbable complexesOxytetracycline Formation of non-absorbable complexesPefloxacin Formation of non-absorbable complexesPolystyrene sulfonate Formation of non-absorbable complexesRisedronate Formation of non-absorbable complexesTetracycline Formation of non-absorbable complexesTrovafloxacin Formation of non-absorbable complexesClodronate Formation of non-absorbable complexesEtidronic acid Formation of non-absorbable complexesMycophenolate mofetil Formation of non-absorbable complexesTemafloxacin Formation of non-absorbable complexes potassium에 대한 Drug_Interactions 정보 Amiloride Increased risk of hyperkaliemiaBenazepril Increased risk of hyperkaliemiaCandesartan Increased risk of hyperkaliemiaCaptopril Increased risk of hyperkaliemiaCilazapril Increased risk of hyperkaliemiaDrospirenone Increased risk of hyperkaliemiaEnalapril Increased risk of hyperkaliemiaEplerenone This association presents an increased risk of hyperkaliemiaEprosartan Increased risk of hyperkaliemiaForasartan Increased risk of hyperkaliemiaFosinopril Increased risk of hyperkaliemiaIrbesartan Increased risk of hyperkaliemiaLisinopril Increased risk of hyperkaliemiaLosartan Increased risk of hyperkaliemiaMoexipril Increased risk of hyperkaliemiaPerindopril Increased risk of hyperkaliemiaPolystyrene sulfonate Antagonism of actionQuinapril Increased risk of hyperkaliemiaRamipril Increased risk of hyperkaliemiaSaprisartan Increased risk of hyperkaliemiaSpirapril Increased risk of hyperkaliemiaSpironolactone Increased risk of hyperkaliemiaTasosartan Increased risk of hyperkaliemiaTelmisartan Increased risk of hyperkaliemiaTrandolapril Increased risk of hyperkaliemiaTriamterene Increased risk of hyperkaliemiaValsartan Increased risk of hyperkaliemia Glycine에 대한 Drug_Interactions 정보 Not Available L-arginine에 대한 Drug_Interactions 정보 Not Available L-cysteine에 대한 Drug_Interactions 정보 Not Available L-histidine에 대한 Drug_Interactions 정보 Not Available L-isoleucine에 대한 Drug_Interactions 정보 Not Available L-lysine에 대한 Drug_Interactions 정보 Not Available
CYP450 Drug Interaction	[CYP450 Table직접조회]
Food Interaction	potassium에 대한 Food Interaction 정보 Not Available
Drug Target	[Drug Target]
Description	Calcium에 대한 Description 정보 Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. potassium에 대한 Description 정보 Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential?봞 "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity. Glycine에 대한 Description 정보 A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem] L-alanine에 대한 Description 정보 A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. [PubChem] L-arginine에 대한 Description 정보 An essential amino acid that is physiologically active in the L-form. [PubChem] L-cysteine에 대한 Description 정보 A thiol-containing non-essential amino acid that is oxidized to form cystine. [PubChem] L-histidine에 대한 Description 정보 An essential amino acid that is required for the production of histamine. [PubChem] L-isoleucine에 대한 Description 정보 An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels. [PubChem] L-leucine에 대한 Description 정보 An essential branched-chain amino acid important for hemoglobin formation. [PubChem] L-lysine에 대한 Description 정보 L-Lysine (abbreviated as Lys or K)[1] is an 慣-amino acid with the chemical formula HO2CCH(NH2)(CH2)4NH2. This amino acid is an essential amino acid, which means that humans cannot synthesize it. Its codons are AAA and AAG.L-Lysine is a base, as are arginine and histidine. The 琯-amino group often participates in hydrogen bonding and as a general base in catalysis. Common posttranslational modifications include methylation of the 琯-amino group, giving methyl-, dimethyl-, and trimethyllysine. The latter occurs in calmodulin. Other posttranslational modifications include acetylation. Collagen contains hydroxylysine which is derived from lysine by lysyl hydroxylase. O-Glycosylation of lysine residues in the endoplasmic reticulum or Golgi apparatus is used to mark certain proteins for secretion from the cell.
Drug Category	Glycine에 대한 Drug_Category 정보 Dietary supplementGlycine AgentsMicronutrientNon-Essential Amino Acids L-alanine에 대한 Drug_Category 정보 Dietary supplementMicronutrientNon-Essential Amino Acids L-arginine에 대한 Drug_Category 정보 Conditionally Essential Amino AcidsDietary supplementMicronutrient L-cysteine에 대한 Drug_Category 정보 Dietary supplementNutritional Supplement L-histidine에 대한 Drug_Category 정보 Conditionally Essential Amino AcidsDietary supplementMicronutrient L-isoleucine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-leucine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient L-lysine에 대한 Drug_Category 정보 Dietary supplementEssential Amino AcidsMicronutrient
Smiles String Canonical	Calcium에 대한 Smiles_String_canonical 정보 Not Available potassium에 대한 Smiles_String_canonical 정보 Not Available Glycine에 대한 Smiles_String_canonical 정보 NCC(O)=O L-alanine에 대한 Smiles_String_canonical 정보 CC(N)C(O)=O L-arginine에 대한 Smiles_String_canonical 정보 NC(CCCN=C(N)N)C(O)=O L-cysteine에 대한 Smiles_String_canonical 정보 NC(CS)C(O)=O L-histidine에 대한 Smiles_String_canonical 정보 NC(CC1=CN=CN1)C(O)=O L-isoleucine에 대한 Smiles_String_canonical 정보 CCC(C)C(N)C(O)=O L-leucine에 대한 Smiles_String_canonical 정보 CC(C)CC(N)C(O)=O L-lysine에 대한 Smiles_String_canonical 정보 NCCCCC(N)C(O)=O
Smiles String Isomeric	Calcium에 대한 Smiles_String_isomeric 정보 Not Available potassium에 대한 Smiles_String_isomeric 정보 Not Available Glycine에 대한 Smiles_String_isomeric 정보 NCC(O)=O L-alanine에 대한 Smiles_String_isomeric 정보 C[C@H](N)C(O)=O L-arginine에 대한 Smiles_String_isomeric 정보 N[C@@H](CCC\N=C(\N)N)C(O)=O L-cysteine에 대한 Smiles_String_isomeric 정보 N[C@@H](CS)C(O)=O L-histidine에 대한 Smiles_String_isomeric 정보 N[C@@H](CC1=CN=CN1)C(O)=O L-isoleucine에 대한 Smiles_String_isomeric 정보 CC[C@H](C)[C@H](N)C(O)=O L-leucine에 대한 Smiles_String_isomeric 정보 CC(C)C[C@@H](N)C(O)=O L-lysine에 대한 Smiles_String_isomeric 정보 NCCCC[C@H](N)C(O)=O
InChI Identifier	Calcium에 대한 InChI_Identifier 정보 Not Available potassium에 대한 InChI_Identifier 정보 Not Available Glycine에 대한 InChI_Identifier 정보 InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)/f/h4H L-alanine에 대한 InChI_Identifier 정보 InChI=1/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1/f/h5H L-arginine에 대한 InChI_Identifier 정보 InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1/f/h11H,8-9H2 L-cysteine에 대한 InChI_Identifier 정보 InChI=1/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1/f/h5H L-histidine에 대한 InChI_Identifier 정보 InChI=1/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1/f/h9-10H L-isoleucine에 대한 InChI_Identifier 정보 InChI=1/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/f/h8H L-leucine에 대한 InChI_Identifier 정보 InChI=1/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/f/h8H L-lysine에 대한 InChI_Identifier 정보 InChI=1/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1/f/h9H
Chemical IUPAC Name	Calcium에 대한 Chemical_IUPAC_Name 정보 Not Available potassium에 대한 Chemical_IUPAC_Name 정보 Not Available Glycine에 대한 Chemical_IUPAC_Name 정보 2-aminoacetic acid L-alanine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-aminopropanoic acid L-arginine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid L-cysteine에 대한 Chemical_IUPAC_Name 정보 (2R)-2-amino-3-sulfanylpropanoic acid L-histidine에 대한 Chemical_IUPAC_Name 정보 (2S)-2-amino-3-(3H-imidazol-4-yl)propanoic acid L-isoleucine에 대한 Chemical_IUPAC_Name 정보 (2S,3S)-2-amino-3-methylpentanoic acid L-leucine에 대한 Chemical_IUPAC_Name 정보 2-amino-4-methylpentanoic acid L-lysine에 대한 Chemical_IUPAC_Name 정보 (2S)-2,6-diaminohexanoic acid
Drug-Induced Toxicity Related Proteins	LYSINE 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Tamm-Horsfall protein Drug:Lysine Toxicity:persisting acute renal failure . [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보